Aclaris Therapeutics Announces Sale of OLUMIANT Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
Aclaris Therapeutics Announces Sale of OLUMIANT Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
Aclaris Therapeutics Announces Sale of OLUMIANT Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
aclaris therapeutics宣佈向omers life sciences出售OLUMIANt專利權和里程碑，最高可達3150萬美元。
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities -
- $26.5 Million Upfront Plus Up to $5.0 Million Milestone -
賓夕法尼亞州韋恩市，2024年7月16日（全球新聞社） - Aclaris Therapeutics, Inc.（NASDAQ：ACRS）是一家專注於開發免疫炎症疾病新型藥物候選品的臨床階段生物製藥公司，今天宣佈將Eli Lilly和Company（Lilly）的OLUMIANT®（baricitinib）銷售的淨銷售額用於治療斑禿'toa部分Aclaris的未來版稅支付和某些里程碑銷售給了OMERS之一，是加拿大最大的規定年金計劃之一。
根據協議條款，Aclaris已收到2650萬美元的預付款，有資格在2024年根據OLUMIANt的某些銷售里程碑的實現情況獲得多達500萬美元的額外支付。作爲交換，OMERS已獲得Lilly應支付給Aclaris用於從2024年4月1日到根據該許可協議的版稅期限結束爲止全球淨銷售額的一部分，以及Lilly在許可協議項下支付給Aclaris的其餘週年里程碑支付的100％。
WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the sale of a portion of Aclaris' future royalty payments and certain milestones from Eli Lilly and Company (Lilly) on net sales of OLUMIANT (baricitinib) for the treatment of alopecia areata to OMERS, one of Canada's largest defined benefit pension plans.
2024年7月16日，宣佈與Eli Lilly and Company（Lilly）就Olumiant(Baricitinib)治療斑禿的全球累計淨銷售額的未來凱瑟琳中Lilly的部分未來的版稅支付和某些里程碑的出售向加拿大最大的養老基金之一 OMERS出售了Aclaris Therapeutics, Inc. (NASDAQ: ACRS)，這是一家專注於開發針對免疫炎性疾病的新型藥物候選品的臨床階段生物製藥公司。
Under the terms of the agreement, Aclaris has received an upfront payment of $26.5 million, and is eligible to receive up to an additional $5.0 million based on the achievement of certain sales milestones for OLUMIANT in 2024. In exchange, OMERS has acquired a portion of the royalty paid by Lilly to Aclaris for worldwide net sales of OLUMIANT for alopecia areata from April 1, 2024 through the remainder of the royalty term under Aclaris' license agreement with Lilly, and 100% of the remaining anniversary milestone payments payable by Lilly to Aclaris under the license agreement.
根據協議的條款，Aclaris Therapeutics已收到2650萬美元的預付款，並有資格根據2024年OLUMIANt銷售中的某些銷售里程碑的實現獲得多達500萬美元的額外費用。作爲交換，OMERS已經獲得了Lilly支付給Aclaris的版稅的一部分，用於斑禿OLUMIANt的全球淨銷售額，從2024年4月1日到Aclaris的許可協議到期的剩餘版稅期限，以及Lilly根據許可協議向Aclaris支付的其餘週年里程碑款項的100%。
"This transaction bolsters our balance sheet and provides us with enhanced financial flexibility to pursue a range of value-creating opportunities while continuing to invest in our internal programs," said Dr. Neal Walker, Interim President & CEO and Chair of the Board of Directors of Aclaris. "As we progress with our strategic review, we will continue to pursue available opportunities to enable us to invest in programs that complement and enhance our existing drug development pipeline."
“這筆交易增強了我們的資產負債表，併爲我們提供了增強的財務靈活性，以追求一系列創造價值的機會，同時繼續投資於我們的內部項目，”Aclaris董事會主席、臨時總裁兼CEO Neal Walker博士表示。“隨着我們戰略審核的進展，我們將繼續尋求可用機會，使我們能夠投資於與我們現有藥物開發管線相補充和增強的項目。”
OLUMIANT is a registered trademark of Eli Lilly and Company.
OLUMIANt是Eli Lilly and Company的註冊商標。
Aclaris Therapeutics Contact:
Aclaris Therapeutics 聯繫方式：
investors@aclaristx.com
investors@aclaristx.com
Source: Aclaris Therapeutics, Inc.
來源：aclairs therapeutics, Inc.
譯文內容由第三人軟體翻譯。